FDA Brief

Warning letters Food

FDA warning letter to

FDC Nutrition Inc.

LowIssued Feb 18, 2021Posted Feb 19, 2021Center for Food Safety and Applied Nutrition (CFSAN)

FDA says FDC Nutrition's Inositol 100% Pure Free Form is an unapproved new drug and misbranded because website claims treat diseases.

What happened

In December 2020, FDA reviewed www.fdcnutrition.com and found the company takes orders there for Inositol 100% Pure Free Form. FDA said label and website claims—such as reducing anxiety by affecting serotonin, aiding blood sugar control, improving fertility in women with PCOS, and reducing depression symptoms—show the product is intended to treat disease. FDA cited the product as an unapproved new drug and misbranded for lacking adequate directions for use.

What FDA found

  1. Website and label claims that the product reduces anxiety, aids blood sugar control, improves fertility in women with PCOS, and reduces depression symptoms make it a drug intended to treat disease.

    section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]
  2. The product is a new drug—not generally recognized as safe and effective for those uses and without FDA approval.

    section 201(p) of the Act [21 U.S.C. § 321(p)]; sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]
  3. The product is misbranded because it lacks adequate directions for use.

    section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 C.F.R. § 201.5
  4. Selling or shipping this misbranded drug in interstate commerce violates the Act.

    section 301(a) of the Act [21 U.S.C. § 331(a)]

What FDA wants

FDA asks FDC Nutrition to notify FDA in writing within 15 working days of receipt, by email to FDAAdvisory@fda.hhs.gov, of steps taken to correct the violations and prevent recurrence, with supporting documents. If it cannot finish in that time, it must state why and when it will.

Who should pay attention

  • supplement brands that make disease-treatment claims
  • retailers and online marketplaces selling inositol products
  • companies marketing products for anxiety, PCOS, depression, or blood sugar

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk